Covalent Ventures

Covalent Ventures has a website, LinkedIn, and Crunchbase presence but the source data discloses no thesis, stage focus, sub-verticals, or check size, and the name overlaps with multiple venture firms internationally. Without firm-specific verification, founders should treat Covalent as a generalist early-stage entity, possibly an emerging manager or family-office-affiliated fund, with no confirmed healthcare specialization. For healthcare AI founders, this means Covalent should not be a top-priority outreach target unless a warm referral or portfolio-company signal surfaces specific healthcare interest. Plausible check sizing in the absence of disclosed data is $100K to $1M, typically as a participant rather than lead, at seed or pre-seed. The firms most plausibly fit are software-style healthcare AI companies, particularly those at the workflow, productivity, or back-office automation layer, rather than clinically deep, regulated, or capital-intensive plays. The entry path runs through LinkedIn outreach to the partners with a direct, specific note that does not assume thesis fit and explicitly asks whether healthcare AI is in scope. Founders should also do reverse diligence: ask Covalent for recent investments, ownership targets, and follow-on history before investing significant pitch time. Honesty about thin public data: this is exactly the kind of profile where founders should not invest more than thirty minutes of preparation until a real signal of interest emerges. Prioritize disclosed-thesis healthcare investors first, and treat Covalent as opportunistic capacity if and when a conversation surfaces.